U.S. markets open in 21 minutes
  • S&P Futures

    4,407.50
    -6.75 (-0.15%)
     
  • Dow Futures

    34,943.00
    -91.00 (-0.26%)
     
  • Nasdaq Futures

    15,122.25
    +4.50 (+0.03%)
     
  • Russell 2000 Futures

    2,199.50
    -13.90 (-0.63%)
     
  • Crude Oil

    71.99
    +0.08 (+0.11%)
     
  • Gold

    1,803.10
    +3.90 (+0.22%)
     
  • Silver

    25.17
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1819
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.2530
    -0.0230 (-1.80%)
     
  • Vix

    18.59
    +1.39 (+8.08%)
     
  • GBP/USD

    1.3817
    -0.0006 (-0.05%)
     
  • USD/JPY

    109.9270
    -0.4480 (-0.41%)
     
  • BTC-USD

    38,413.65
    +184.50 (+0.48%)
     
  • CMC Crypto 200

    914.60
    -0.89 (-0.10%)
     
  • FTSE 100

    6,997.78
    -27.65 (-0.39%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Global Celiac Disease Clinical Trial Pipeline Report 2021-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

·2 min read

DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Celiac Disease Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Celiac Disease Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Celiac Disease market.

It covers emerging therapies for Celiac Disease in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Celiac Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Celiac Disease pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Celiac Disease pipeline products by the company.

Short-term Launch Highlights:

Find out which Celiac Disease pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Celiac Disease phase 3 clinical trial pipeline products

  • Celiac Disease phase 2 clinical trial pipeline products

  • Celiac Disease phase 1 clinical trial pipeline products

  • Celiac Disease preclinical research pipeline products

  • Celiac Disease discovery stage pipeline products

  • Celiac Disease pipeline products short-term launch highlights

Countries Covered

  • Global

  • Europe

  • US

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/ivh4oc

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005660/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900